Medicine:Chronic kidney disease
|Chronic kidney disease|
|Other names||Chronic renal disease, kidney failure, impaired kidney function|
|Illustration of a kidney from a person with chronic renal failure|
Later: Leg swelling, feeling tired, vomiting, loss of appetite, confusion
|Complications||Heart disease, high blood pressure, anemia|
|Causes||Diabetes, high blood pressure, glomerulonephritis, polycystic kidney disease|
|Diagnostic method||Blood tests, urine tests|
|Treatment||Medications to manage blood pressure, blood sugar, and lower cholesterol, renal replacement therapy, kidney transplant|
|Frequency||753 million (2016)|
|Deaths||1.2 million (2015)|
Chronic kidney disease (CKD) is a type of kidney disease in which a gradual loss of kidney function occurs over a period of months to years. Initially generally no symptoms are seen, but later symptoms may include leg swelling, feeling tired, vomiting, loss of appetite, and confusion. Complications can relate to hormonal dysfunction of the kidneys and include (in chronological order) high blood pressure (often related to activation of the renin–angiotensin system system), bone disease, and anemia. Additionally CKD patients have markedly increased cardiovascular complications with increased risks of death and hospitalization.
Causes of chronic kidney disease include diabetes, high blood pressure, glomerulonephritis, and polycystic kidney disease. Risk factors include a family history of chronic kidney disease. Diagnosis is by blood tests to measure the estimated glomerular filtration rate (eGFR), and a urine test to measure albumin. Ultrasound or kidney biopsy may be performed to determine the underlying cause. Several severity-based staging systems are in use.
Screening at-risk people is recommended. Initial treatments may include medications to lower blood pressure, blood sugar, and cholesterol. Angiotensin converting enzyme inhibitors (ACEIs) or angiotensin II receptor antagonists (ARBs) are generally first-line agents for blood pressure control, as they slow progression of the kidney disease and the risk of heart disease. Loop diuretics may be used to control edema and, if needed, to further lower blood pressure. NSAIDs should be avoided. Other recommended measures include staying active, and certain dietary changes such as a low-salt diet and the right amount of protein. Treatments for anemia and bone disease may also be required. Severe disease requires hemodialysis, peritoneal dialysis, or a kidney transplant for survival.
Chronic kidney disease affected 753 million people globally in 2016 - 417 million females and 336 million males. In 2015, it caused 1.2 million deaths, up from 409,000 in 1990. The causes that contribute to the greatest number of deaths are high blood pressure at 550,000, followed by diabetes at 418,000, and glomerulonephritis at 238,000.
Signs and symptoms
CKD is initially without symptoms, and is usually detected on routine screening blood work by either an increase in serum creatinine, or protein in the urine. As the kidney function decreases, more unpleasant symptoms may emerge:
- Blood pressure is increased due to fluid overload and production of vasoactive hormones created by the kidney via the renin–angiotensin system, increasing the risk of developing hypertension and heart failure. People with CKD are more likely than the general population to develop atherosclerosis with consequent cardiovascular disease, an effect that may be at least partly mediated by uremic toxins. People with both CKD and cardiovascular disease have significantly worse prognoses than those with only cardiovascular disease.
- Urea accumulates, leading to azotemia and ultimately uremia (symptoms ranging from lethargy to pericarditis and encephalopathy). Due to its high systemic concentration, urea is excreted in eccrine sweat at high concentrations and crystallizes on skin as the sweat evaporates ("uremic frost").
- Potassium accumulates in the blood (hyperkalemia with a range of symptoms including malaise and potentially fatal cardiac arrhythmias). Hyperkalemia usually does not develop until the glomerular filtration rate falls to less than 20–25 mL/min/1.73 m2, when the kidneys have decreased ability to excrete potassium. Hyperkalemia in CKD can be exacerbated by acidemia (which leads to extracellular shift of potassium) and from lack of insulin.
- Fluid overload symptoms may range from mild edema to life-threatening pulmonary edema.
- Hyperphosphatemia results from poor phosphate elimination in the kidney, and contributes to increased cardiovascular risk by causing vascular calcification. Circulating concentrations of fibroblast growth factor-23 (FGF-23) increase progressively as the kidney capacity for phosphate excretion declines, which may contribute to left ventricular hypertrophy and increased mortality in people with CKD .
- Hypocalcemia results from 1,25 dihydroxyvitamin D3 deficiency (caused by high FGF-23 and reduced kidney mass) and resistance to the action of parathyroid hormone. Osteocytes are responsible for the increased production of FGF-23, which is a potent inhibitor of the enzyme 1-alpha-hydroxylase (responsible for the conversion of 25-hydroxycholecalciferol into 1,25 dihydroxyvitamin D3). Later, this progresses to secondary hyperparathyroidism, kidney osteodystrophy, and vascular calcification that further impairs cardiac function. An extreme consequence is the occurrence of the rare condition named calciphylaxis.
- Changes in mineral and bone metabolism that may cause 1) abnormalities of calcium, phosphorus (phosphate), parathyroid hormone, or vitamin D metabolism; 2) abnormalities in bone turnover, mineralization, volume, linear growth, or strength (kidney osteodystrophy); and 3) vascular or other soft-tissue calcification. CKD-mineral and bone disorders have been associated with poor outcomes.
- Metabolic acidosis may result from decreased capacity to generate enough ammonia from the cells of the proximal tubule. Acidemia affects the function of enzymes and increases excitability of cardiac and neuronal membranes by the promotion of hyperkalemia.
- Anemia is common and is especially prevalent in those requiring haemodialysis. It is multifactorial in cause, but includes increased inflammation, reduction in erythropoietin, and hyperuricemia leading to bone-marrow suppression. Hypoproliferative anemia occurs due to inadequate production of erythropoietin by the kidneys.
- In later stages, cachexia may develop, leading to unintentional weight loss, muscle wasting, weakness, and anorexia.
- Sexual dysfunction is very common in both men and women with CKD. A majority of men have a reduced sex drive, difficulty obtaining an erection, and reaching orgasm, and the problems get worse with age. Most women have trouble with sexual arousal, and painful menstruation and problems with performing and enjoying sex are common.
The three most common causes of CKD in order of frequency as of 2015 are diabetes mellitus, hypertension, and glomerulonephritis. About one of five adults with hypertension and one of three adults with diabetes have CKD. If the cause is unknown, it is called idiopathic.
By anatomical location
- Vascular disease includes large-vessel disease such as bilateral kidney artery stenosis and small-vessel disease such as ischemic nephropathy, hemolytic-uremic syndrome, and vasculitis.
- Glomerular disease comprises a diverse group and is classified into:
- Primary glomerular disease such as focal segmental glomerulosclerosis and IgA nephropathy (or nephritis)
- Secondary glomerular disease such as diabetic nephropathy and lupus nephritis
- Tubulointerstitial disease includes drug- and toxin-induced chronic tubulointerstitial nephritis, and reflux nephropathy
- Obstructive nephropathy, as exemplified by bilateral kidney stones and benign prostatic hyperplasia of the prostate gland; rarely, pinworms infecting the kidney can cause obstructive nephropathy.
- Genetic congenital disease such as polycystic kidney disease or 17q12 microdeletion syndrome.
- Mesoamerican nephropathy, is "a new form of kidney disease that could be called agricultural nephropathy". A high and so-far unexplained number of new cases of CKD, referred to as the Mesoamerican nephropathy, has been noted among male workers in Central America, mainly in sugarcane fields in the lowlands of El Salvador and Nicaragua. Heat stress from long hours of piece-rate work at high average temperatures of about 36 °C (96 °F) is suspected, as are agricultural chemicals
Diagnosis of CKD is largely based on history, examination, and urine dipstick combined with the measurement of the serum creatinine level (see above). Differentiating CKD from acute kidney injury (AKI) is important because AKI can be reversible. One diagnostic clue that helps differentiate CKD from AKI is a gradual rise in serum creatinine (over several months or years) as opposed to a sudden increase in the serum creatinine (several days to weeks). In many people with CKD, previous kidney disease or other underlying diseases are already known. A significant number present with CKD of unknown cause.
Screening those who have neither symptoms nor risk factors for CKD is not recommended. Those who should be screened include: those with hypertension or history of cardiovascular disease, those with diabetes or marked obesity, those aged > 60 years, subjects with African American ancestry, those with a history of kidney disease in the past, and subjects who have relatives who had kidney disease requiring dialysis.
Screening should include calculation of the estimated GFR (eGFR) from the serum creatinine level, and measurement of urine albumin-to-creatinine ratio (ACR) in a first-morning urine specimen (this reflects the amount of a protein called albumin in the urine), as well as a urine dipstick screen for hematuria.
The GFRis derived from the serum creatinine and is proportional to 1/creatinine, i.e. it is a reciprocal relationship; the higher the creatinine, the lower the GFR. It reflects one aspect of kidney function, how efficiently the glomeruli - the filtering units - work. Normal GFR is 90-120 ml/min. The units of creatinine vary from country to country, but since the glomeruli make up <5% of the mass of the kidney, the GFR does not indicate all aspects of kidney health and function. This can be done by combining the GFR level with the clinical assessment of the person, including fluid status, and measuring the levels of hemoglobin, potassium, phosphate, and parathyroid hormone.
Kidney ultrasonography is useful for diagnostic and prognostic purposes in chronic kidney disease. Whether the underlying pathologic change is glomerular sclerosis, tubular atrophy, interstitial fibrosis, or inflammation, the result is often increased echogenicity of the cortex. The echogenicity of the kidney should be related to the echogenicity of either the liver or the spleen (Figure 22 and Figure 23). Moreover, decreased kidney size and cortical thinning are also often seen and especially when disease progresses (Figure 24 and Figure 25). However, kidney size correlates to height, and short persons tend to have small kidneys; thus, kidney size as the only parameter is not reliable.
Chronic renal disease caused by glomerulonephritis with increased echogenicity and reduced cortical thickness. Measurement of kidney length on the US image is illustrated by '+' and a dashed line.
Nephrotic syndrome. Hyperechoic kidney without demarcation of cortex and medulla.
Chronic pyelonephritis with reduced kidney size and focal cortical thinning. Measurement of kidney length on the US image is illustrated by '+' and a dashed line.
End-stage chronic kidney disease with increased echogenicity, homogenous architecture without visible differentiation between parenchyma and renal sinus and reduced kidney size. Measurement of kidney length on the US image is illustrated by '+' and a dashed line.
Additional tests may include nuclear medicine MAG3 scan to confirm blood flow and establish the differential function between the two kidneys. Dimercaptosuccinic acid (DMSA) scans are also used in kidney imaging; with both MAG3 and DMSA being used chelated with the radioactive element technetium-99.
|Chronic kidney disease (CKD) staging - CKD G1-5 A1-3 |
glomerular filtration rate (GFR) and albumin/creatinine ratio (ACR)
|Normal to mildly increased||Moderately increased||Severely increased|
|G1||Normal||≥ 90||1 if kidney damage present||1||2|
|G2||Mildly decreased||60-89||1 if kidney damage present||1||2|
|G3a||Mildly to moderately decreased||45-59||1||2||3|
|G3b||Moderately to severely decreased||30-44||2||3||3|
|Numbers 1 - 4 indicates risk of progression as well as frequency of monitoring (number of times a year). |
Kidney Disease Improving Global Outcomes - KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease 
A glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m2 is considered normal without chronic kidney disease if there is no kidney damage present.
Kidney damage is defined signs of damage seen in blood, urine, or imaging studies which includes lab albumin/creatinine ratio (ACR) ≥ 30. All people with a GFR <60 mL/min/1.73 m2 for 3 months are defined as having chronic kidney disease.
Protein in the urine is regarded as an independent marker for worsening of kidney function and cardiovascular disease. Hence, British guidelines append the letter "P" to the stage of chronic kidney disease if protein loss is significant.
- Stage 1: Slightly diminished function; kidney damage with normal or relatively high GFR (≥90 mL/min/1.73 m2) and persistent albuminuria. Kidney damage is defined as pathological abnormalities or markers of damage, including abnormalities in blood or urine tests or imaging studies.
- Stage 2: Mild reduction in GFR (60–89 mL/min/1.73 m2) with kidney damage. Kidney damage is defined as pathological abnormalities or markers of damage, including abnormalities in blood or urine tests or imaging studies.
- Stage 3: Moderate reduction in GFR (30–59 mL/min/1.73 m2):. British guidelines distinguish between stage 3A (GFR 45–59) and stage 3B (GFR 30–44) for purposes of screening and referral.
- Stage 4: Severe reduction in GFR (15–29 mL/min/1.73 m2) Preparation for kidney replacement therapy.
- Stage 5: Established kidney failure (GFR <15 mL/min/1.73 m2), permanent kidney replacement therapy, or end-stage kidney disease.
The term "non-dialysis-dependent chronic kidney disease" (NDD-CKD) is a designation used to encompass the status of those persons with an established CKD who do not yet require the life-supporting treatments for kidney failure known as kidney replacement therapy (RRT, including maintenance dialysis or kidney transplantation). The condition of individuals with CKD, who require either of the two types of kidney replacement therapy (dialysis or transplant), is referred to as the end-stage kidney disease (ESKD). Hence, the start of the ESKD is practically the irreversible conclusion of the NDD-CKD. Even though the NDD-CKD status refers to the status of persons with earlier stages of CKD (stages 1 to 4), people with advanced stage of CKD (stage 5), who have not yet started kidney replacement therapy, are also referred to as NDD-CKD.
Apart from controlling other risk factors, the goal of therapy is to slow down or halt the progression of CKD. Control of blood pressure and treatment of the original disease are the broad principles of management.
Angiotensin converting enzyme inhibitors (ACEIs) or angiotensin II receptor antagonists (ARBs) are recommended as first-line agents since they have been found to slow the decline of kidney function, relative to a more rapid decline in those not on one of these agents. They have also been found to reduce the risk of major cardiovascular events such as myocardial infarction, stroke, heart failure, and death from cardiovascular disease when compared to placebo in individuals with CKD. ACEIs may be superior to ARBs for protection against progression to kidney failure and death from any cause in those with CKD. Aggressive blood pressure lowering decreases people's risk of death.
- Aggressive treatment of high blood lipids is recommended.
- A low-protein, low-salt diet may result in slower progression of CKD and reduction in proteinuria as well as controlling symptoms of advanced CKD to delay dialysis start. A tailored low-protein diet, designed for low acidity, may help prevent damage to kidneys for people with CKD. Additionally, controlling salt ingestion helps to decrease the incidence of coronary heart disease, lowering blood pressure and reducing albuminuria.
- Anemia - A target hemoglobin level of 9–12 g/dL is recommended; raising hemoglobin levels to the normal range has not been found to be of benefit.
- Guidelines recommend treatment with parenteral iron prior to treatment with erythropoietin.
- Replacement of erythropoietin is often necessary in people with advanced disease.
- It is unclear if androgens improve anemia.
- Calcitriol is recommended for vitamin D deficiency and control of metabolic bone disease.
- Phosphate binders are used to control the serum phosphate levels, which are usually elevated in advanced chronic kidney disease.
- Phosphodiesterase-5 inhibitors and zinc may improve sexual dysfunction in men.
Obesity may have a negative impact in CKD, increasing the risk of disease progression to ESKD or kidney failure compared to controls with healthy weight, and when in advanced stages also may hinder people's eligibility to kidney transplantation. For example, the consumption of high calorie and high fructose beverages can make an individual "60% more likely to develop CKD".
Weight management interventions in overweight and obese adults with CKD (of various stages) have been studied to assess its safety and efficacy. A recent systematic review collected evidence from 17 studies which evaluated lifestyle (including dietary, physical activity/exercise, or behavioural strategies used in isolation or in combination), pharmacological (used to reduce absorption or suppress appetite) and surgical interventions. The review concluded that lifestyle interventions may provide some health benefits, namely improving body weight, low density lipoprotein (LDL) cholesterol and diastolic blood pressure (DBP), when compared to usual care or controls. Whether these benefits extend to help reducing cardiovascular events, kidney function and risk of death is uncertain. These conclusions were based on very low quality of evidence, so future robust studies are needed. Thus, it is recommended that weight management interventions should be individualised, according to a thorough patients' assessment regarding clinical condition, motivations and preferences.
Dietary salt intake
High dietary sodium intake may increase the risk of hypertension and cardiovascular disease. The effect of dietary restriction of salt in foods has been investigated in people with chronic kidney disease. A 2021 Cochrane review of controlled trials in people with CKD at any stage, including those on dialysis, found high-certainty evidence that reduced salt intake may help to lower both systolic and diastolic blood pressure, as well as albuminuria. However there was also moderate certainty evidence that some people may experience hypotensive symptoms, such as dizziness, following sudden sodium restriction. It is unclear whether this affects the dosage required for anti-hypertensive medications. The effect of salt restriction on extracellular fluid, oedema, and total body weight reduction was also uncertain.
Omega-3 fatty acid supplementation
In people with CKD who require hemodialysis, there is a risk that vascular blockage due to clotting, may prevent dialysis therapy from being possible. Omega-3 fatty acids contribute to the production of eicosanoid molecules that reduce clotting. However, a Cochrane review in 2018 did not find clear evidence that omega-3 supplementation has any impact on the prevention of vascular blockage in people with CKD. There was also moderate certainty that supplementation did not prevent hospitalisation or death within a 12-month period.
There is moderate-certainty evidence that regular consumption of oral protein-based nutritional supplements may increase serum albumin levels slightly in people with CKD, especially among those requiring hemodialysis or who are malnourished. Pre-albumin levels and mid-arm circumference measurements may also be increased following supplementation, though the certainty of evidence is low. Despite possible improvement in these indicators of nutritional status, it is not certain that protein supplements affect quality of life, life expectancy, inflammation or body composition.
A Cochrane review of controlled trials comparing intravenous (IV) iron therapy with oral iron supplements, found low-certainty evidence that people receiving IV-iron treatment were 1.71 times as likely to reach their target hemoglobin levels. Overall, hemoglobin was 0.71g/dl higher than those treated with oral iron supplements. Iron stores in the liver, estimated by serum ferritin, were also 224.84 µg/L higher in those receiving IV-iron. However there was also low-certainty evidence that allergic reactions were more likely following IV-iron therapy. It was unclear whether type of iron therapy administration affects the risk of death from any cause, including cardiovascular, nor whether it may alter the number of people who may require a blood transfusion or dialysis.
People with CKD experience sleep disorders, thus not being able to get quality sleep. There are several strategies that could help, such as relaxation techniques, exercise, acupressure and medication:
- Exercise: weak evidence demonstrates that exercise may be helpful with sleep regulation. Nevertheless, exercise possibly decreases fatigue and depression in people with CKD.
- Acupressure: evidence suggests that this technique may have slight effects on latency and sleep duration, as well as on fatigue reduction, although these results are not reliable due to the diversity of conclusions in several articles.
Despite all the available options studied so far, evidence shows that none of them is effective in the treatment of sleep disorders. This means that we are not able to conclude which is the best guidance to improve sleep quality in this type of population.
There is currently limited evidence suggesting that eHealth interventions may improve dietary sodium intake and fluid management for people with chronic kidney disease (CKD). The findings are based on low certainty evidence of 43 studies. So, more large and higher quality research studies are needed to understand the impact of eHealth on the health of people with CKD.
Referral to a nephrologist
Guidelines for referral to a nephrologist vary between countries. Most agree that nephrology referral is required by Stage 4 CKD (when eGFR/1.73m2 is less than 30 mL/min; or decreasing by more than 3 mL/min/year).
It may also be useful at an earlier stage (e.g. CKD3) when urine albumin-to-creatinine ratio is more than 30 mg/mmol, when blood pressure is difficult to control, or when hematuria or other findings suggest either a primarily glomerular disorder or secondary disease amenable to specific treatment. Other benefits of early nephrology referral include proper education regarding options for kidney replacement therapy as well as pre-emptive transplantation, and timely workup and placement of an arteriovenous fistula in those people with chronic kidney disease opting for future hemodialysis.
Renal replacement therapy
At stage 5 CKD, kidney replacement therapy is usually required, in the form of either dialysis or a kidney transplant.
In CKD numerous uremic toxins accumulate in the blood. Even when ESKD (largely synonymous with CKD5) is treated with dialysis, the toxin levels do not go back to normal as dialysis is not that efficient. Similarly, after a kidney transplant, the levels may not go back to normal as the transplanted kidney may not work 100%. If it does, the creatinine level is often normal. The toxins show various cytotoxic activities in the serum and have different molecular weights, and some of them are bound to other proteins, primarily to albumin. Uremic toxins are classified into three groups as small water-soluble solutes, middle molecular-weight solutes, and protein-bound solutes. Hemodialysis with high-flux dialysis membrane, long or frequent treatment, and increased blood/dialysate flow has improved removal of water-soluble small molecular weight uremic toxins. Middle molecular weight molecules are removed more effectively with hemodialysis using a high-flux membrane, hemodiafiltration and hemofiltration. However, conventional dialysis treatment is limited in its ability to remove protein-bound uremic toxins.
CKD increases the risk of cardiovascular disease, and people with CKD often have other risk factors for heart disease, such as high blood lipids. The most common cause of death in people with CKD is cardiovascular disease rather than kidney failure.
Chronic kidney disease results in worse all-cause mortality (the overall death rate) which increases as kidney function decreases. The leading cause of death in chronic kidney disease is cardiovascular disease, regardless of whether there is progression to stage 5.
While kidney replacement therapies can maintain people indefinitely and prolong life, the quality of life is negatively affected. Kidney transplantation increases the survival of people with stage 5 CKD when compared to other options; however, it is associated with an increased short-term mortality due to complications of the surgery. Transplantation aside, high-intensity home hemodialysis appears to be associated with improved survival and a greater quality of life, when compared to the conventional three-times-a-week hemodialysis and peritoneal dialysis.
People with ESKD are at increased overall risk for cancer. This risk is particularly high in younger people and gradually diminishes with age. Medical specialty professional organizations recommend that physicians do not perform routine cancer screening in people with limited life expectancies due to ESKD because evidence does not show that such tests lead to improved outcomes.
In children, growth failure is a common complication from CKD. Children with CKD will be shorter than 97% of children the same age and sex. This can be treated with additional nutritional support, or medication such as Growth hormone
About one in ten people have chronic kidney disease. In Canada 1.9 to 2.3 million people were estimated to have CKD in 2008. CKD affected an estimated 16.8% of U.S. adults aged 20 years and older in the period from 1999 to 2004. In 2007 8.8% of the population of Great Britain and Northern Ireland had symptomatic CKD.
Chronic kidney disease was the cause of 956,000 deaths globally in 2013, up from 409,000 deaths in 1990.
Chronic kidney disease of unknown aetiology
The cause of chronic kidney disease is in some cases not known; it is referred to as chronic kidney disease of unknown aetiology (CKDu). (As of 2020) a rapidly progressive chronic kidney disease, unexplained by diabetes and hypertension, had increased dramatically in prevalence over a few decades in several regions in Central America and Mexico, a CKDu referred to as the Mesoamerican nephropathy (MeN). It was estimated in 2013 that at least 20,000 men had died prematurely, some in their 20s and 30s; a figure of 40,000 per year was estimated in 2020. In some affected areas CKD mortality was five times the national rate. MeN primarily affects men working as sugarcane labourers. The cause is unknown, but in 2020 the science found a clearer connection between heavy labour in high temperatures and incidence of CKDu; improvements such as regular access to water, rest and shade, can significantly decrease the potential CKDu incidence. CKDu also affects people in Sri Lanka where it is the eighth largest cause of in-hospital mortality.
Although CKDu was first documented among sugar cane workers in Costa Rica in the 1970s, it may well have affected plantation labourers since the introduction of sugar cane farming to the Caribbean in the 1600s. In colonial times the death records of slaves on sugar plantations was much higher than for slaves forced into other labour.
African, Hispanics, and South Asians, particularly those from Pakistan, Sri Lanka, Bangladesh, and India, are at high risk of developing CKD. Africans are at greater risk due to the number of people affected with hypertension among them. As an example, 37% of ESKD cases in African Americans can be attributed to high blood pressure, compared with 19% among Caucasians. Treatment efficacy also differs between racial groups. Administration of antihypertensive drugs generally halts disease progression in white populations but has little effect in slowing kidney disease among black people, and additional treatment such as bicarbonate therapy is often required. While lower socioeconomic status contributes to the number of people affected with CKD, differences in the number of people affected by CKD are still evident between Africans and Whites when controlling for environmental factors.
Society and culture
The International Society of Nephrology is an international body representing specialists in kidney diseases.
- The National Kidney Foundation is a national organization representing people with chronic kidney diseases and professionals who treat kidney diseases.
- The American Kidney Fund is a national nonprofit organization providing treatment-related financial assistance to one of every five people undergoing dialysis each year.
- The Renal Support Network is a nonprofit, patient-focused, patient-run organization that provides non-medical services to those affected by CKD.
- The American Association of Kidney Patients is a nonprofit, patient-centric group focused on improving the health and well-being of CKD and people undergoing dialysis .
- The Renal Physicians Association is an association representing nephrology professionals.
It was said to be costing the National Health Service about £1.5 billion a year in 2020.
Kidney Care UK and The UK National Kidney Federation represent people with chronic kidney disease. The Renal Association represents Kidney physicians and works closely with the National Service Framework for kidney disease.
Kidney Health Australia serves that country.
The incidence rate of CKD in dogs was 15.8 cases per 10,000 dog years at risk. The mortality rate of CKD was 9.7 deaths per 10,000 dog years at risk. (rates developed from a population of 600,000 insured Swedish dogs; one dog year at risk is one dog at risk for one year)The breeds with the highest rates were the Bernese mountain dog, miniature schnauzer and boxer. The Swedish elkhound, Siberian husky and Finnish spitz were the breeds with the lowest rates.
Currently, several compounds are in development for the treatment of CKD. These include the angiotensin receptor blocker (ARB) olmesartan medoxomil; and sulodexide, a mixture of low molecular weight heparin and dermatan sulfate.
Unbiased research with complete reporting is required to determine the safety and effectiveness of acupuncture to treat depression, pain, sleep problems, and uraemic pruritus in people who are undergoing dialysis treatments on a regular basis.
- ↑ 1.0 1.1 1.2 "Disparities in Chronic Kidney Disease Prevalence among Males and Females in 195 Countries: Analysis of the Global Burden of Disease 2016 Study". Nephron 139 (4): 313–318. 23 May 2018. doi:10.1159/000489897. PMID 29791905. https://zenodo.org/record/1283108.
- ↑ 2.0 2.1 2.2 2.3 2.4 "What Is Chronic Kidney Disease?". June 2017. https://www.niddk.nih.gov/health-information/kidney-disease/chronic-kidney-disease-ckd/what-is-chronic-kidney-disease.
- ↑ 3.0 3.1 "Insulin resistance in patients with chronic kidney disease". Journal of Biomedicine & Biotechnology 2012: 691369. 2012. doi:10.1155/2012/691369. PMID 22919275.
- ↑ 4.0 4.1 "Kidney Failure" (in en). https://medlineplus.gov/kidneyfailure.html.
- ↑ 5.0 5.1 5.2 5.3 5.4 "What is renal failure?" (in en). https://www.hopkinsmedicine.org/healthlibrary/conditions/kidney_and_urinary_system_disorders/end_stage_renal_disease_esrd_85,P01474.
- ↑ 6.0 6.1 6.2 6.3 6.4 "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet 388 (10053): 1459–1544. October 2016. doi:10.1016/s0140-6736(16)31012-1. PMID 27733281.
- ↑ 7.0 7.1 7.2 "Chronic Kidney Disease Tests & Diagnosis". October 2016. https://www.niddk.nih.gov/health-information/kidney-disease/chronic-kidney-disease-ckd/tests-diagnosis.
- ↑ 8.0 8.1 "Kidney Failure". https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure.
- ↑ 9.0 9.1 9.2 9.3 9.4 "Managing Chronic Kidney Disease". October 2016. https://www.niddk.nih.gov/health-information/kidney-disease/chronic-kidney-disease-ckd/managing.
- ↑ 10.0 10.1 10.2 KDIGO: Kidney Disease Improving Global Outcomes (August 2009). "KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)". Kidney Int 76 (Suppl 113). http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO%20CKD-MBD%20GL%20KI%20Suppl%20113.pdf.
- ↑ "Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization". The New England Journal of Medicine 351 (13): 1296–1305. September 2004. doi:10.1056/NEJMoa041031. PMID 15385656.
- ↑ "Summary of Recommendation Statements". Kidney International Supplements 3 (1): 5–14. January 2013. doi:10.1038/kisup.2012.77. PMID 25598998.
- ↑ (in en) Ferri's Clinical Advisor 2018 E-Book: 5 Books in 1. Elsevier Health Sciences. 2017. pp. 294–295. ISBN 9780323529570. https://books.google.com/books?id=wGclDwAAQBAJ&pg=PA294.
- ↑ 14.0 14.1 14.2 14.3 "Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials". American Journal of Kidney Diseases 67 (5): 728–41. May 2016. doi:10.1053/j.ajkd.2015.10.011. PMID 26597926.
- ↑ "Diuretics: a review". Annals of Clinical Biochemistry 49 (Pt 5): 419–31. September 2012. doi:10.1258/acb.2011.011281. PMID 22783025.
- ↑ "2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)". JAMA 311 (5): 507–20. February 2014. doi:10.1002/14651858.CD011339.pub2. PMID 24352797.
- ↑ "Eating Right for Chronic Kidney Disease | NIDDK". https://www.niddk.nih.gov/health-information/kidney-disease/chronic-kidney-disease-ckd/eating-nutrition.
- ↑ "Anemia in Chronic Kidney Disease". July 2016. https://www.niddk.nih.gov/health-information/kidney-disease/chronic-kidney-disease-ckd/anemia.
- ↑ "Mineral & Bone Disorder in Chronic Kidney Disease". November 2015. https://www.niddk.nih.gov/health-information/kidney-disease/chronic-kidney-disease-ckd/mineral-bone-disorder.
- ↑ 20.0 20.1 "Osteoblastogenesis of adipose-derived mesenchymal stem cells in chronic kidney disease patient with regular hemodialysis". Annals of Medicine and Surgery 84: 104796. December 2022. doi:10.1016/j.amsu.2022.104796. PMID 36536732.
- ↑ 21.0 21.1 "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013". Lancet 385 (9963): 117–71. January 2015. doi:10.1016/S0140-6736(14)61682-2. PMID 25530442. Table 2, p. 137
- ↑ "Patient-centred approaches for the management of unpleasant symptoms in kidney disease". Nat Rev Nephrol 18 (2): 001–017. Jan 3, 2022. doi:10.1038/s41581-021-00518-z. PMID 34980890.
- ↑ "Uremic Toxins Activate Macrophages". Circulation 139 (1): 97–100. January 2019. doi:10.1161/CIRCULATIONAHA.118.037308. PMID 30592654.
- ↑ "Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis". European Heart Journal 35 (7): 455–69. February 2014. doi:10.1093/eurheartj/eht386. PMID 24164864.
- ↑ 25.0 25.1 "Chronic Kidney Disease". Medscape. 2018-09-16. http://emedicine.medscape.com/article/238798-overview#aw2aab6b2b2.
- ↑ "Hyperphosphatemia of chronic kidney disease". Kidney International 74 (2): 148–57. July 2008. doi:10.1038/ki.2008.130. PMID 18449174.
- ↑ "FGF23 induces left ventricular hypertrophy". The Journal of Clinical Investigation 121 (11): 4393–408. November 2011. doi:10.1172/JCI46122. PMID 21985788.
- ↑ "Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis". The New England Journal of Medicine 359 (6): 584–92. August 2008. doi:10.1056/NEJMoa0706130. PMID 18687639.
- ↑ "Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes". Journal of Bone and Mineral Research 28 (1): 46–55. January 2013. doi:10.1002/jbmr.1740. PMID 22886720.
- ↑ "The calcemic response to PTH in the rat: effect of elevated PTH levels and uremia". Kidney International 46 (2): 310–7. August 1994. doi:10.1038/ki.1994.276. PMID 7967341.
- ↑ Harrison's Principles of Internal Medicine (18th ed.). New York: McGraw-Hill. 2012. p. 3109. ISBN 978-0-07-174890-2.
- ↑ "Calciphylaxis: a still unmet challenge". Journal of Nephrology 24 (2): 142–8. 2011. doi:10.5301/jn.2011.6366. PMID 21337312.
- ↑ "Changes in plasma potassium concentration during acute acid-base disturbances". The American Journal of Medicine 71 (3): 456–67. September 1981. doi:10.1016/0002-9343(81)90182-0. PMID 7025622.
- ↑ "Anemia Of Chronic Renal Disease". StatPearls [Internet]. StatPearls Publishing. January 2021. NBK539871. https://www.ncbi.nlm.nih.gov/books/NBK539871/.
- ↑ "Wasting in chronic kidney disease". Journal of Cachexia, Sarcopenia and Muscle 2 (1): 9–25. March 2011. doi:10.1007/s13539-011-0019-5. PMID 21475675.
- ↑ 36.0 36.1 "Interventions for treating sexual dysfunction in patients with chronic kidney disease". The Cochrane Database of Systematic Reviews (12): CD007747. December 2010. doi:10.1002/14651858.CD007747.pub2. PMID 21154382.
- ↑ "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet 388 (10053): 1545–1602. October 2016. doi:10.1016/S0140-6736(16)31678-6. PMID 27733282.
- ↑ "United States Renal Data System (USRDS)". http://www.usrds.org/.
- ↑ "Epidemiology of chronic kidney disease in adults of Salvadoran agricultural communities". MEDICC Review 16 (2): 23–30. April 2014. doi:10.37757/MR2014.V16.N2.5. PMID 24878646. http://www.medicc.org/mediccreview/index.php?issue=28&id=351&a=va.
- ↑ Tangri N (29 July 2013). "MesoAmerican Nephropathy: A New Entity". eAJKD. National Kidney Foundation. http://ajkdblog.org/2013/07/29/mesoamerican-nephropathy-a-new-entity/.
- ↑ 41.0 41.1 "The epidemic of chronic kidney disease of unknown etiology in Mesoamerica: a call for interdisciplinary research and action". American Journal of Public Health 103 (11): 1927–30. November 2013. doi:10.2105/AJPH.2013.301594. PMID 24028232.
- ↑ "Chronic kidney disease: Mesoamerican nephropathy--new clues to the cause". Nature Reviews. Nephrology 9 (10): 560–1. October 2013. doi:10.1038/nrneph.2013.174. PMID 23999393.
- ↑ "Fructokinase activity mediates dehydration-induced renal injury". Kidney International 86 (2): 294–302. August 2014. doi:10.1038/ki.2013.492. PMID 24336030.
- ↑ "Global heating 'may lead to epidemic of kidney disease'" (in en). 2021-10-21. https://www.theguardian.com/global-development/2021/oct/21/global-heating-may-lead-to-epidemic-of-kidney-disease.
- ↑ "Thousands of sugar cane workers die as wealthy nations stall on solutions". International Consortium of Investigative Journalists. 12 December 2011. http://www.icij.org/project/island-widows/thousands-sugar-cane-workers-die-wealthy-nations-stall-solutions.
- ↑ "Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians". Annals of Internal Medicine 159 (12): 835–47. December 2013. doi:10.7326/0003-4819-159-12-201312170-00726. PMID 24145991.
- ↑ "Diagnosis and management of non-dialysis chronic kidney disease in ambulatory care: a systematic review of clinical practice guidelines". BMC Nephrology 19 (1): 258. October 2018. doi:10.1186/s12882-018-1048-5. PMID 30305035.
- ↑ "Chapter 4: CKD Screening and Management: Overview". Handbook of Chronic Kidney Disease Management. Lippincott Williams and Wilkins. 2011-05-02. pp. 32–43. ISBN 978-1-58255-893-6. http://hdcn.com/CKDhandbook/toc.htm.
- ↑ 49.0 49.1 49.2 49.3 49.4 Content initially copied from: "Ultrasonography of the Kidney: A Pictorial Review". Diagnostics 6 (1): 2. December 2015. doi:10.3390/diagnostics6010002. PMID 26838799. (CC-BY 4.0)
- ↑ "Kidney scans". https://www.singhealth.com.sg/patient-care/conditions-treatments/kidney-scans/overview.
- ↑ CKD Evaluation and Management 2012. Kidney Disease Improving Global Outcomes (KDIGO). Retrieved 2019-07-06.
- ↑ 52.0 52.1 52.2 52.3 52.4 52.5 52.6 National Kidney Foundation (2002). "K/DOQI clinical practice guidelines for chronic kidney disease". http://www.kidney.org/professionals/KDOQI/guidelines_ckd.
- ↑ 53.0 53.1 National Institute for Health and Clinical Excellence. Clinical guideline 73: Chronic kidney disease. London, 2008.
- ↑ "Chronic Kidney Disease". Lancet 397 (10293): 001–017. Jun 24, 2021. doi:10.1016/S0140-6736(21)00519-5. PMID 34175022. https://researchonline.lshtm.ac.uk/id/eprint/4663580/1/Kalantar-Zadeh_etal_2021-Preserving-Kidney-Function-in-People.pdf.
- ↑ "Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis". JAMA Internal Medicine 177 (10): 1498–1505. October 2017. doi:10.1001/jamainternmed.2017.4377. PMID 28873137.
- ↑ "Dyslipidemia in chronic kidney disease: managing a high-risk combination". Postgraduate Medicine 121 (6): 54–61. November 2009. doi:10.3810/pgm.2009.11.2077. PMID 19940417.
- ↑ "Nutritional Management of Chronic Kidney Disease". The New England Journal of Medicine 377 (18): 1765–1776. November 2017. doi:10.1056/NEJMra1700312. PMID 29091561. https://escholarship.org/uc/item/02m5c6qr.
- ↑ "Reducing the Dietary Acid Load: How a More Alkaline Diet Benefits Patients With Chronic Kidney Disease". J Ren Nutr 27 (3): 151–160. May 2017. doi:10.1053/j.jrn.2016.11.006. PMID 28117137.
- ↑ "Altered dietary salt intake for people with chronic kidney disease". The Cochrane Database of Systematic Reviews 2021 (6): CD010070. June 2021. doi:10.1002/14651858.cd010070.pub3. PMID 34164803.
- ↑ "Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study". Nephrology, Dialysis, Transplantation 25 (9): 2846–50. September 2010. doi:10.1093/ndt/gfq336. PMID 20591813.
- ↑ "The impact of selecting a high hemoglobin target level on health-related quality of life for patients with chronic kidney disease: a systematic review and meta-analysis". Archives of Internal Medicine 169 (12): 1104–12. June 2009. doi:10.1001/archinternmed.2009.112. PMID 19546410.
- ↑ 62.0 62.1 "Guidelines for the management of chronic kidney disease". CMAJ 179 (11): 1154–62. November 2008. doi:10.1503/cmaj.080351. PMID 19015566.
- ↑ "Anaemia management in people with chronic kidney disease (CG114)". NICE Clinical Guideline. UK National Institute for Health and Care Excellence. February 2011. http://guidance.nice.org.uk/CG114.
- ↑ "Androgens for the anaemia of chronic kidney disease in adults". The Cochrane Database of Systematic Reviews 10 (10): CD006881. October 2014. doi:10.1002/14651858.CD006881.pub2. PMID 25300168.
- ↑ "The dose-response relationship between body mass index and the risk of incident stage ≥3 chronic kidney disease in a general japanese population: the Ibaraki prefectural health study (IPHS)". Journal of Epidemiology 24 (6): 444–451. 2014. doi:10.2188/jea.JE20140028. PMID 24998954.
- ↑ "Obesity and the risk of cardiovascular and all-cause mortality in chronic kidney disease: a systematic review and meta-analysis". Nephrology, Dialysis, Transplantation 32 (3): 439–449. March 2017. doi:10.1093/ndt/gfw075. PMID 27190330.
- ↑ "High-fructose corn syrup-sweetened soft drink consumption increases vascular resistance in the kidneys at rest and during sympathetic activation". American Journal of Physiology. Renal Physiology 318 (4): F1053–F1065. April 2020. doi:10.1152/ajprenal.00374.2019. PMID 32174139.
- ↑ "Associations of sugar-sweetened and artificially sweetened soda with chronic kidney disease: a systematic review and meta-analysis". Nephrology 19 (12): 791–797. December 2014. doi:10.1111/nep.12343. PMID 25251417.
- ↑ "Interventions for weight loss in people with chronic kidney disease who are overweight or obese". The Cochrane Database of Systematic Reviews 2021 (3): CD013119. March 2021. doi:10.1002/14651858.CD013119.pub2. PMID 33782940.
- ↑ 70.0 70.1 "Altered dietary salt intake for people with chronic kidney disease". The Cochrane Database of Systematic Reviews 2021 (6): CD010070. June 2021. doi:10.1002/14651858.CD010070.pub3. PMID 34164803.
- ↑ 71.0 71.1 "Omega-3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease". The Cochrane Database of Systematic Reviews 2018 (11): CD011353. November 2018. doi:10.1002/14651858.CD011353.pub2. PMID 30480758.
- ↑ 72.0 72.1 72.2 "Oral protein-based supplements versus placebo or no treatment for people with chronic kidney disease requiring dialysis". The Cochrane Database of Systematic Reviews 5 (5): CD012616. May 2020. doi:10.1002/14651858.CD012616.pub2. PMID 32390133.
- ↑ 73.0 73.1 73.2 "Parenteral versus oral iron therapy for adults and children with chronic kidney disease". The Cochrane Database of Systematic Reviews 2 (2): CD007857. February 2019. doi:10.1002/14651858.CD007857.pub3. PMID 30790278.
- ↑ 74.0 74.1 74.2 74.3 74.4 74.5 "Interventions for improving sleep quality in people with chronic kidney disease". The Cochrane Database of Systematic Reviews 5 (5): CD012625. May 2019. doi:10.1002/14651858.cd012625.pub2. PMID 31129916.
- ↑ 75.0 75.1 "eHealth interventions for people with chronic kidney disease". The Cochrane Database of Systematic Reviews 2019 (8): CD012379. August 2019. doi:10.1002/14651858.cd012379.pub2. PMID 31425608.
- ↑ "CKD Stage 4". https://www.davita.com/education/kidney-disease/stages/stage-4-of-chronic-kidney-disease.
- ↑ "Review on uremic toxins: classification, concentration, and interindividual variability". Kidney International 63 (5): 1934–43. May 2003. doi:10.1046/j.1523-1755.2003.00924.x. PMID 12675874.
- ↑ "Removal of uremic toxins by renal replacement therapies: a review of current progress and future perspectives". Renal Replacement Therapy 2 (1). 14 September 2016. doi:10.1186/s41100-016-0056-9.
- ↑ 79.0 79.1 "Increased mortality in chronic kidney disease: a call to action". The American Journal of the Medical Sciences 331 (3): 150–3. March 2006. doi:10.1097/00000441-200603000-00007. PMID 16538076.
- ↑ "Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention". Circulation 108 (17): 2154–69. October 2003. doi:10.1161/01.CIR.0000095676.90936.80. PMID 14581387.
- ↑ "Chronic kidney disease and mortality risk: a systematic review". Journal of the American Society of Nephrology 17 (7): 2034–47. July 2006. doi:10.1681/ASN.2005101085. PMID 16738019. http://jasn.asnjournals.org/cgi/content/full/17/7/2034.
- ↑ "Quality of life". Daily and Nocturnal Hemodialysis. Contributions to Nephrology. 145. 2004. 99–105. doi:10.1159/000081673. ISBN 978-3-8055-7808-0.
- ↑ "Challenges and future of renal replacement therapy". Hemodialysis International 10 (Suppl 1): S19-23. January 2006. doi:10.1111/j.1542-4758.2006.01185.x. PMID 16441862.
- ↑ "Long-term outcomes of children with end-stage renal disease". Pediatric Nephrology 20 (7): 849–53. July 2005. doi:10.1007/s00467-005-1878-9. PMID 15834618.
- ↑ "Choice of renal replacement therapy in patients with diabetic end stage renal disease". EDTNA/ERCA Journal 30 (3): 138–42. 2004. doi:10.1111/j.1755-6686.2004.tb00353.x. PMID 15715116.
- ↑ "Quotidian dialysis--update 2005". Current Opinion in Nephrology and Hypertension 14 (2): 119–24. March 2005. doi:10.1097/00041552-200503000-00006. PMID 15687837. https://zenodo.org/record/896982.
- ↑ 87.0 87.1 "Cancer in patients on dialysis for end-stage renal disease: an international collaborative study". Lancet 354 (9173): 93–9. July 1999. doi:10.1016/S0140-6736(99)06154-1. PMID 10408483.
- ↑ American Society of Nephrology. "Five Things Physicians and Patients Should Question". Choosing Wisely: An Initiative of the ABIM Foundation. http://choosingwisely.org/wp-content/uploads/2012/04/5things_12_factsheet_Amer_Soc_Neph.pdf. Retrieved August 17, 2012.
- ↑ "Cost-effectiveness of cancer screening in end-stage renal disease". Archives of Internal Medicine 156 (12): 1345–50. June 1996. doi:10.1001/archinte.1996.00440110117016. PMID 8651845.
- ↑ "Growth Failure in Children with Chronic Kidney Disease | NIDDK" (in en-US). https://www.niddk.nih.gov/health-information/kidney-disease/children/caring-child-kidney-disease/growth-failure-chronic-kidney-disease.
- ↑ Centers for Disease Control Prevention (CDC) (March 2007). "Prevalence of chronic kidney disease and associated risk factors--United States, 1999-2004". MMWR. Morbidity and Mortality Weekly Report 56 (8): 161–5. PMID 17332726. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5608a2.htm.
- ↑ Morgan T (21 January 2009). "Chronic Kidney Disease (stages 3–5) prevalence estimates using data from the Neoerica study (2007)". Association of Public Health Observatories. http://www.apho.org.uk/resource/item.aspx?RID=63798.
- ↑ 93.0 93.1 "The mystery epidemic striking Nicaragua's sugar cane workers – a photo essay". The Guardian. 27 November 2020. https://www.theguardian.com/global-development/2020/nov/27/the-mystery-epidemic-striking-nicaraguas-sugar-cane-workers-a-photo-essay.
- ↑ "CKD of Unknown Etiology (CKDu) in Sri Lanka: A Multilevel Clinical Case Definition for Surveillance and Epidemiological Studies". Kidney International Reports 4 (6): 781–785. June 2019. doi:10.1016/j.ekir.2019.03.020. PMID 31194108.
- ↑ 95.0 95.1 95.2 "Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans". Archives of Internal Medicine 168 (8): 832–9. April 2008. doi:10.1001/archinte.168.8.832. PMID 18443258.
- ↑ "Tackling the £1.5bn a year cost of chronic kidney disease". Health Service Journal (Southfields, Essex, UK: Wilmington Healthcare Limited). 20 March 2020. https://www.hsj.co.uk/the-hsj-awards/tackling-the-15-billion-a-year-cost-of-chronic-kidney-disease/7027154.article.
- ↑ (in en) Chronic kidney disease in the dog. 2018. ISBN 978-91-7760-208-8. https://pub.epsilon.slu.se/15458/. Retrieved 8 June 2018.
- ↑ "Incidence of and mortality from kidney disease in over 600,000 insured Swedish dogs". The Veterinary Record 176 (25): 656. June 2015. doi:10.1136/vr.103059. PMID 25940343.
- ↑ Clinical trial number NCT00151827 for "Olmesartan Medoxomil in Hypertension and Renal Impairment" at ClinicalTrials.gov
- ↑ "Angiotensin II Receptor Blockers (ARBs)". MedicineNet. 20 December 2019. https://www.medicinenet.com/angiotensin_ii_receptor_blockers/article.htm#what_are_the_side_effects_of_arbs.
- ↑ "Acupuncture and related interventions for symptoms of chronic kidney disease". The Cochrane Database of Systematic Reviews 2016 (6): CD009440. June 2016. doi:10.1002/14651858.CD009440.pub2. PMID 27349639.
- Dialysis Complications of Chronic Renal Failure at eMedicine
- Chronic Renal Failure Information from Great Ormond Street Hospital
- [./Https://www.mybestpdf.com/world-diabetes-day-2022/ How to Prevent Chronic Kidney Disease n World Diabetes Day 2022]
Original source: https://en.wikipedia.org/wiki/Chronic kidney disease. Read more